Cannabinoid-based pharmaceutical preparations
By Estudio Chaloupka
Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, entered into a partnership with an Argentine pharmaceutical company to register and commercialize Avicanna’s proprietary cannabinoid-based pharmaceutical preparations through the licensing of its intellectual property and supply of its active pharmaceutical ingredients (“API”).Through the partnership Avicanna will provide a non-exclusive license of the Company’s intellectual property related to its proprietary 10% cannabidiol (“CBD”) pharmaceutical drug preparation. Additionally, the partner will source its pharmaceutical-grade CBD exclusively from Avicanna to manufacture the product for the registration and marketing authorization with the Argentine regulatory agency ANMAT.
The marketing authorization of the pharmaceutical preparation is expected to be approved during the second half of 2022 and is expected to be supported with claims related to treatment of epilepsy. The estimated patient population and market potential for epilepsy in Argentina is between 400,000 to 500,000 patients of which about 20,000 patients have refractory epilepsy.
